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PRECIS FOR USE IN THE TABLE OF CONTENTS 
• In this propensity score-adjusted multi-Institutional series, doxorubicin+dacarbazine 
showed the better outcomes for the first-line treatment of advanced leiomyosarcoma 
warranting further studies 









Background: Optimal treatment for advanced leiomyosarcoma is still debated. In the lack of 
histotype-specific prospective controlled data, we retrospectively evaluated 
doxorubicin+dacarbazine, doxorubicin+ifosfamide and doxorubicin alone as first-line treatment for 
advanced/metastatic leiomyosarcoma treated within EORTC-STBSG sites. 
Methods: Inclusion criteria: confirmed histological diagnosis, treatment between 1/2010 and 
12/2015, measurable disease (RECIST1.1), ECOG performance status ≤2, age ≥18 years. 
Endpoints: progression-free survival (PFS), overall survival (OS), overall response rate (ORR). PFS 
was analyzed using methods for interval-censored data. Patients were matched according to their 
propensity scores estimated using a logistic regression model accounting for histology, grade, age, 
gender, performance status, tumor site and extent.  
Results: 303 patients from 18 EORTC-STBSG sites were identified. 117(39%) received 
doxorubicin+dacarbazine, 71(23%) doxorubicin+ifosfamide, and 115(38%) doxorubicin. In the 
2:1:2 propensity score-matched population (205 patients), estimated median PFS was 9.2 (5.2-97), 
8.2 (5.2-10.1), and 4.8 months (2.3-6.0), with an ORR of 30.9%, 19.5%, and 25.6% for 
doxorubicin+dacarbazine, doxorubicin+ifosfamide, and doxorubicin alone, respectively. PFS was 
significantly longer for doxorubicin+dacarbazine vs. doxorubicin [HR 0.72(0.52-0.99)]. 
Doxorubicin+dacarbazine reported longer OS [median 36.8 months(27.9-47.2)] compared to both 
doxorubicin+ifosfamide [21.9 (16.7-33.4), HR 0.65(0.40-1.06)] and doxorubicin [30.3 (21.0-36.3), 
HR 0.66(0.43-0.99]. Adjusted analyses retained effect for PFS but not for OS. None of the factors 
selected for multivariate analysis had significant interaction with the received treatment for both 
PFS and OS. 
Conclusions: This is the largest retrospective study on first-line treatment for advanced 
leiomyosarcoma. In the propensity score-matched population doxorubicin+dacarbazine showed 
















Soft tissue sarcomas (STS) are a heterogeneous group of tumors encompassing more than 50 
different entities. Leiomyosarcoma is one of the most common histotypes representing about 10-
20% of all STS.1,2 This tumor may arise in any site of the body, being retroperitoneum, limbs/girdles, 
and uterus more frequently affected.1,2 Despite the absence of distinctive morphologic features, there 
is some genetic and clinical evidence supporting that site of origin may affect both sensitivity to 
treatments and prognosis.1-7 
Overall, leiomyosarcoma management is multidisciplinary, but surgery still represents the 
cornerstone of treatment in localized disease. Unfortunately, despite optimal locoregional 
treatments, leiomyosarcoma may relapse.1,2,8-10 For patients with metastatic disease, first-line 
chemotherapy is currently based on anthracyclines, including doxorubicin alone or in combination 
with ifosfamide or dacarbazine.11-13  
Whatever treatment is used, complete remission is a rare event and second- and further-line 
therapies obtain poor results with only anecdotal long-term survivors.14 Furthermore, 
chemosensitivity in STS may vary substantially according to histotype and administered drug. On 
this basis, cytotoxics for the second- and further-line setting are now increasingly chosen following 
a histology-driven approach.15 Indeed, the latest randomized phase 3 trials that led to drug approval 
(pazopanib,16 trabectedin,17,18 and eribulin19,20) have emphasized this strategy. Unfortunately, the 
histotype-tailored approach failed to overcome the results of anthracyclines-based regimens in the 
neoadjuvant setting.21,22 
In this context, it has been retrospectively observed that ifosfamide has limited activity in 
leiomyosarcomas,23 whereas dacarbazine demonstrated favorable results both as single agent and in 
combination with gemcitabine.18,20,24,25 More than 30 years ago, doxorubicin was compared to 
doxorubicin+dacarbazine in patients affected by advanced uterine sarcomas and carcinosarcomas. 
No significant survival advantage or response rate improvement was demonstrated with the 




leiomyosarcoma the combination achieved a response rate of 30% (6 out 20 evaluable patients).26 
Hence, dacarbazine is increasingly used in combination with doxorubicin as first-line treatment for 
advanced leiomyosarcoma,11,12,27-31 despite we lack a formal prospective evidence to support this 
choice. 
In this scenario of relative uncertainty and in the lack of ongoing controlled prospective studies, we 
have gathered a large retrospective series of patients affected by advanced/metastatic 
leiomyosarcoma treated with first-line anthracycline-based regimens within EORTC Soft Tissue 
and Bone Sarcoma Group (STBSG) referral centers to compare doxorubicin+dacarbazine with 
doxorubicin either alone or in combination with ifosfamide. 
 
PATIENTS AND METHODS 
Patients Selection 
This was a multicenter, retrospective study involving reference Institutions within the EORTC 
STBSG (Table S1). After approval from the Institutional Review Board and/or Ethic Committee of 
participating Institutions, patients who met the following criteria were included: histologically 
confirmed and non-surgically resectable or metastatic leiomyosarcoma (including leiomyosarcoma 
with pleomorphic features);1 first-line treatment for metastatic disease with doxorubicin either alone 
or in combination with ifosfamide or dacarbazine started between January 2010 and December 
2015; measurable disease (RECIST 1.1); Eastern Cooperative Oncology Group (ECOG) 
Performance Status of 0-2; age ≥18 years. Patients with major comorbidities that might jeopardize 
the interpretation of the data were excluded (i.e., another malignancy within the previous 5 years, 
or other severe and/or uncontrolled concurrent medical disease). 
 
Outcomes 
The primary objective of this study was to explore the activity of doxorubicin+dacarbazine, 
doxorubicin+ifosfamide and doxorubicin alone as first-line treatments for non-resectable/metastatic 




(OS), and RECIST 1.1 overall response rate (ORR). PFS duration was estimated by an interval-
censoring method that accounts for the variable schedules of follow-up measurements in the routine 
clinical practice.32 Details on endpoints measurement are reported in the appendix (page 2). Data on 
subsequent treatments were keenly collected. 
Due to the absence of randomization we performed matching of patients across treatment arms using 
a propensity score, i.e. an estimate of the probability of each patient to receive one of the three 
treatments. 33-35 We used a 2:1:2 matching ratio resembling the distribution of treatments between 
the three arms observed in the dataset and then, as a sensitivity analysis, we conducted pairwise 1:1 
matching of the three possible treatment pairs. Details on the propensity score methods are available 
in the appendix (page 2, 7-19; Figure S1-S3; Table S5-S11). 
 
Statistical Analysis 
Statistical analyses were performed using SAS statistical software v9.4. A p-value ≤0.05 was 
considered statistically significant. We provide descriptive statistics for population characteristics. 
Qualitative variables were compared using the χ2 and Fisher's exact tests. Tests were two-sided and 
results were reported with 95% confidence intervals (95%CI) or interquartile ranges (IQR) 
whenever indicated. ORRs were compared among treatment arms by means of the odds ratio (OR) 
estimates obtained from logistic regression. In order to determine potential predictive factors 
(histology, site of primary, age, gender, ECOG performance status, tumor extent, and FNCLCC 
grade) and their related effects, a full multivariate analysis with the administered chemotherapy as 
additional covariate was run using the interval-censored and the Cox model with Firth adjustment 
for PFS and OS, respectively. Wald p-values were computed to evaluate the interaction between 
administered chemotherapy and each factor. 
 
RESULTS 
303 patients treated at 18 different EORTC STBSG Institutions from nine European countries were 




distribution of chemotherapy across the 18 contributing institution were observed (Table S1). The 
first-line treatment was doxorubicin plus dacarbazine for 117 (38.6%), doxorubicin plus ifosfamide 
for 71 (23.4%), and doxorubicin alone for 115 (38.0%) patients. Baseline characteristics of the 
studied population are reported in Table 1. As expected, fewer patients younger than 50-year-old 
and more patients over 70-year-old were treated with doxorubicin alone compared to combination 
regimens. Other characteristics were similar across the three arms with the exception of an excess 
of inoperable, locally advanced disease without metastases for doxorubicin+ifosfamide arm. At the 
time of data cutoff (December 22, 2017), only one patient in the doxorubicin+dacarbazine arm was 
still on treatment. Median number of administered cycles were six, three, and five for 
doxorubicin+dacarbazine, doxorubicin+ifosfamide and doxorubicin alone, respectively. Table 2 
reports further details on chemotherapy regimens. 
At the time of analysis, the overall median follow-up was 41 months for the whole series (IQR: 
26.3-56.7), with shorter follow-up for doxorubicin+dacarbazine [31.7 months (IQR: 23.1-47.2)] 
compared to both doxorubicin+ifosfamide and doxorubicin alone [50 months (IQR: 37.3-72.7), and 
46.1 months (IQR: 31.3-58.4), respectively]. Indeed, patients receiving doxorubicin+dacarbazine 
were treated more recently and more patients who received this regimen were lost to follow-up or 
censored for OS. Notably, subsequent treatments were well balanced across the three arms (Table 
S2). 
 
Unmatched population  
Overall, in the 303 patients included in the database, unadjusted median PFS was 9.4 (95%CI 6.1-
9.7), 6.8 (4.5-9.5), 5.4 (3.8-6.8) months (Figure 2A, p=0.0723, df=2) with a 6-month PFS rate of 
57.9% (48.0-66.5%), 43.9% (23.9-57.3%), 45% (35.3-54.2%), and an observed ORR of 36.8%, 
21.5%, and 25.9%, for doxorubicin+dacarbazine, doxorubicin+ifosfamide and doxorubicin alone, 
respectively. Median OS was 35.4 (28.7-45.7), 21.4 (16.7-26.7), and 29.3 (21.4-33.4) months 




56.0% (46.1-64.8%) for doxorubicin+dacarbazine, doxorubicin+ifosfamide and doxorubicin alone, 
respectively.  
Adjusting for all baseline factors (histology, site of primary, age, gender, ECOG performance status, 
tumor extent, and FNCLCC grade) revealed a significant difference in terms of PFS for 
doxorubicin+dacarbazine vs. doxorubicin (HR 0.60, 95%CI:0.44-0.82, p=0.0014) but not for 
doxorubicin+ifosfamide vs. doxorubicin HR 0.79 (95%CI: 0.56-1.10). There was no significant 
difference between groups in terms of OS (HR for doxorubicin + dacarbazine and for doxorubicin 
+ ifosfamide vs. doxorubicin were 0.78 (95%CI: 0.52-1.16) and 1.21 (95%CI: 0.82-1.79), 
respectively). 
Predictive factors 
None of the factors included in the multivariate analysis (age, sex, ECOG PS, histotype, site of 
primary tumor, tumor grade, and tumor extent) appeared predictive for treatment effect in terms of 
both PFS and OS based on interaction tests (appendix pages 5-6, Table S3-S4). We observed a trend 
toward a worse outcome for uterine vs. non-uterine origin especially for patients who received 
doxorubicin alone. Nonetheless, this difference did not reach significance in the overall population 
and the number of patients affected by uterine leiomyosarcoma did not allow to further explore 
differences based on site of origin of the primary tumor. 
 
Matched population 
After propensity score matching of 205 patients with a 2:1:2 ratio, demographic and baseline tumor 
characteristics were well balanced with no significant differences between the three arms with the 
exception of tumor extent that retained an excess of patients with locally advanced disease without 
metastases in the doxorubicin+ifosfamide arm (Table 1, Figure S1-S3).  
In the 2:1:2 matched population, doxorubicin+dacarbazine showed a significantly longer PFS 
compared to doxorubicin alone [median 9.2 months (95%CI 5.2-9.7) vs. 4.8 (2.3-6.0); HR 0.72 
(0.52-0.99)], but not to doxorubicin+ifosfamide [8.2 months (5.2-10.1), HR 1.01 (0.68-1.50)]. PFS 




1.06)]. Estimated 6-month PFS rates were 58.2% (46.4-68.3%), 47.1% (31.5-61.2%), and 42.4% 
(31.0-53.1%) for doxorubicin+dacarbazine, doxorubicin+ifosfamide, and doxorubicin alone, 
respectively (Figure 2B). 
In the same 2:1:2 matched population, ORR was 30.9% with doxorubicin+dacarbazine, 19.5% with 
doxorubicin+ifosfamide, and 25.6% with doxorubicin alone [OR 1.70 (0.68-4.24) for 
doxorubicin+dacarbazine vs. doxorubicin+ifosfamide; OR 1.26 (0.63-2.50) for 
doxorubicin+dacarbazine vs. doxorubicin alone; and OR 0.74 (0.29-1.86) for 
doxorubicin+ifosfamide vs. doxorubicin alone]. 
The estimated median OS was longer with doxorubicin+dacarbazine [36.8 months (95%CI 27.9-
47.2)] compared to both doxorubicin+ifosfamide [21.9 months (95%CI 16.7-33.4), HR 0.65 (95%CI 
0.40-1.06)] and doxorubicin alone [30.3 months (95%CI 21.0-36.3), HR 0.66 (95%CI 0.43-0.99)] 
(Figure 3B). OS rates at 12- and 24-month were 81.5% (70.8-88.6%) and 69.6% (57.8-78.7%) with 
doxorubicin+dacarbazine, 82.9% (67.5-91.5%) and 49.5% (33.1-63.9%) with 
doxorubicin+ifosfamide, 76.3% (65.4-84.2) and 59.0% (47.2-69.1%) with doxorubicin alone. 
Indeed, survival curves started to separate after 18 months (Figure 3B).  
 
Adjusted analysis in the matched population 
Since there remained minor imbalances in baseline characteristics after matching (Table 1), we also 
performed comparisons adjusted for baseline factors. The difference between treatments in terms of 
PFS was statistically significant (p=0.0023 overall) with HR 0.53 (95%CI 0.36-0.77, p=0.0009) for 
doxorubicin+dacarbazine vs. doxorubicin and HR 0.58 (95%CI 0.38-0.89, p=0.0135) for 
doxorubicin+ifosfamide vs. doxorubicin. There was no significant difference between groups in 
terms of OS (p=0.2089) with HR 0.70 (95%CI 0.44-1.13, p=0.1433) for doxorubicin+dacarbazine 







Population characteristics of the new dataset of patients (Figure S1-S3, Table S5-S11) as well as 
results of the three pairwise matched populations obtained with a 1:1 ratio are reported in the 
supplementary appendix (Figure S4-S6; Table S12-S14; Figure S7-S9). 
 
DISCUSSION 
To our knowledge, this is the largest retrospective study investigating the value of first line treatment 
for advanced leiomyosarcoma. Despite the limitations of a retrospective study, we observed 
intriguing signs of activity for doxorubicin and dacarbazine combination both in the unadjusted and 
in the propensity-score-matched population. In particular, median PFS and ORR were above 9 
months and 30%, respectively. These results favorably compare with both historical controls and 
the results observed with either doxorubicin+ifosfamide or doxorubicin alone in our study.13,36-38 
Notably, outcomes of the doxorubicin+dacarbazine arm were also consistent with the few data 
previously reported for this combination in leiomyosarcomas.26,29 Furthermore, although 
retrospective, the outcomes observed in the doxorubicin alone and in the doxorubicin+ifosfamide 
arms are consistent with the ones reported in the randomized EORTC 62012 study using the same 
regimens [median PFS for leiomyosarcoma patients: 6.1 and 6.6 months, respectively (unpublished 
data)].13 
Looking at our data from another perspective, this study confirms the limited role of ifosfamide in 
leiomyosarcoma.23,39 Indeed, patients who received this drug reported the lowest response rate and 
lowest median OS among the three arms, with only a non-significant trend toward an improved PFS 
compared to doxorubicin alone. Given the retrospective nature of the study, we cannot draw 
definitive conclusions. Nonetheless, taking also into consideration the relevant toxicities associated 
with ifosfamide, the use of this drug in leiomyosarcomas should be considered with caution. 
Notably, we observed a marked difference in treatment choice across reference Centers in Europe 
that reflects the current uncertainty on the topic that prompted our study. In particular, some Centers 
used mainly doxorubicin in combination with either dacarbazine or ifosfamide, whereas others 




are consistent with guidelines and literature data.12,39 As frequently observed in clinical practice, 
doxorubicin in combination with either ifosfamide or dacarbazine was seldom used at a slightly 
lower dose than the one used when the drug is delivered as monotherapy (nearly 60 vs. 75 mg/m2, 
respectively). Nonetheless, this difference was not statistically significant.  
Putting our data in the clinical context of advanced leiomyosarcoma, doxorubicin alone or 
gemcitabine+docetaxel (+/- bevacizumab) demonstrated a median PFS of about 6 months with a 
response rate ranging from 10 to 30% at most.13,37,38 We decided not to include in our analysis the 
combination of gemcitabine+docetaxel or the MAID protocol (MESNA, doxorubicin, ifosfamide, 
and dacarbazine)30 since very few patients have been treated in the first-line setting with these 
regimens across the 18 reference Centers that contributed in this study. A notable exception in the 
field of first-line treatments for leiomyosarcoma is represented by the combination of doxorubicin 
and trabectedin that, up to now, obtained the most promising results. Indeed, in a phase 2, open-
label, single-arm study, patients stratified according to uterine and non-uterine origin reported a 
median PFS of 8 and 13 months with an ORR of about 60% and 40%, respectively.5 A phase 3 
randomized study comparing this combination with doxorubicin alone in advanced 
leiomyosarcomas is currently ongoing (NCT02997358), whereas a phase 2 randomized trial that 
included all STS histotypes did not demonstrate benefit from the addition of trabectedin to 
doxorubicin.40 More recently, preliminary data from the ANNOUNCE trial did not confirm the 
survival advantage of adding olaratumab to doxorubicin in all STS as well as in 
leiomyosarcoma.36,41 
In our study, the observed OS seems particularly promising and is consistent with the expected 
longer survival in leiomyosarcoma patients compared to the general sarcoma population.2,42 
In our multi-institutional series, the doxorubicin+dacarbazine arm showed the longest survival both 
in the unadjusted and in the propensity-score-matched population, but the shorter follow-up of this 
arm weakens the comparison among the three regimens. Although a median follow-up of 32 months 
could be considered adequate in the STS setting being more than two times longer than the expected 




indeed lead to an overestimation of OS by means of Kaplan-Meier method. Despite this potential 
issue in OS evaluation, the follow-up length does not affect PFS estimation. 
The limitations of the present study are mainly related to its retrospective nature. As mentioned 
above, there is a potential bias in center-specific chemotherapy preference. Moreover, as in the great 
majority of retrospective studies, we did not perform a central pathological review of the diagnosis 
or a central review of radiological responses. Nonetheless, both these potential issues are limited by 
the fact that data came from reference centers across Europe. Indeed, the great majority of the 
diagnoses have been confirmed by reference sarcoma pathologists in each country, and disease 
responses have been reviewed by the involved investigator(s) at each site according to RECIST 1.1. 
Another potential bias is related to the risk of PFS overestimation due to longer time intervals 
between CT scans that could delay disease progression detection. Nonetheless, the risk of this bias 
was greatly limited by our choice of an interval-censoring approach to the data analysis. This choice 
allowed for a better PFS estimation that, as mentioned above, was superimposable to the outcomes 
observed in the prospective EORTC 62012 trial for both doxorubicin alone and 
doxorubicin+ifosfamide arm.13  
In the lack of prospective randomized studies and in light of the negative results of the ANNOUNCE 
trial, data from analyses based on adjustment for baseline covariates and propensity score matching 
represent a relevant source of information although they should remain mainly hypothesis-
generating. Propensity score allowed us to reduce the bias related to treatment allocation in a non-
randomized, retrospective study and was based on the most relevant covariates available in our 
database. However, matching has the limitation to diminish the total number of matched patients to 
the arm with the lowest recruitment (in our study doxorubicin+ifosfamide), thus reducing the power 
of the analysis and limiting the generalization of the estimated effect.33-35 That said, the results of 
adjusted analyses in the matched and unmatched populations appear consistent and suggest that PFS 





In conclusion, our study showed that doxorubicin and dacarbazine combination is an intriguing 
treatment option for leiomyosarcoma that deserves further investigations in prospective trials. 
Indeed, based on these results, a phase 3 randomized study is currently being developed within the 
frame of the EORTC Soft Tissue and Bone Sarcoma Group aiming to explore the role of 
neoadjuvant doxorubicin+dacarbazine compared to surgery alone in patients affected by high grade, 
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Figure 1. CONSORT diagram. 
Figure 2. Progression-free survival. Panel A, unadjusted population; Panel B, 2:1:2 propensity-
score-matched population for the three treatment arms. Purple line doxorubicin plus dacarbazine, 
blue line doxorubicin plus ifosfamide, red line doxorubicin alone. 
Figure 3. Overall survival. Panel A, unadjusted population; Panel B, 2:1:2 propensity-score-
matched population for the three treatment arms. Purple line doxorubicin plus dacarbazine, blue 
line doxorubicin plus ifosfamide, red line doxorubicin alone. 
 
 
 
 
